Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 17/20 | 0.45 |
| ▸ | EGFR | P00533 | 12/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193902 | 0.92 | ERBB2 (0.44) | ERBB2EGFRERBB4JAK3 | |
| SCHEMBL2194630 | 0.89 | ERBB2 (0.54) | ERBB2EGFR | |
| SCHEMBL2191370 | 0.87 | ERBB2 (0.44) | ERBB2EGFRERBB4JAK3 | |
| SCHEMBL2192988 | 0.85 | ERBB2 (0.45) | ERBB2EGFRERBB4JAK3 | |
| SCHEMBL2195013 | 0.85 | ERBB2 (0.43) | ERBB2EGFRERBB4TNNI3KJAK3 | |
| SCHEMBL2194036 | 0.85 | ERBB2 (0.43) | ERBB2EGFRERBB4JAK3 | |
| SCHEMBL2194533 | 0.84 | ERBB2 (0.48) | ERBB2EGFR | |
| SCHEMBL2193798 | 0.82 | ERBB2 (0.51) | ERBB2EGFR | |
| SCHEMBL2195622 | 0.82 | ERBB2 (0.58) | ERBB2EGFRKCNH2 | |
| SCHEMBL2196938 | 0.82 | EGFR (0.53) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | ERBB2 1762/4885EGFR 2146/4885KCNH2 4503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.